Should You Buy United Therapeutics Corporation Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, United Therapeutics Corporation (UTHR) ranks in the top tier of our coverage universe with a Quality of Company score of 9.6/10. Trading at a market price of $500.35, this high-quality profile requires careful comparison against our 13 intrinsic value models.
The short answer: 6 of 11 CirclFi valuation models project upside for United Therapeutics Corporation (UTHR) at $500.35 — the model consensus leans bullish, with a Quality Score of 9.6/10 and Value-Trap risk of 8/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for United Therapeutics Corporation (UTHR) in 2026?
What Is the Bull Case vs the Bear Case for United Therapeutics Corporation (UTHR)?
| Bull case — $1105.10 target (+120.9%) | Bear case — $330.16 target (-34.0%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, United Therapeutics Corporation's quality score of 9.6/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation. | According to the CirclFi Deep Alpha Valuation Engine, the EROIC Spread model sees the stock as overvalued with a fair value of $330.16 (-34.0%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Markov DDM model targets a fair value of $1,105.10 (+120.9%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +154.9% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| Industry tailwind: regulatory pathway clarity could provide meaningful support for United Therapeutics Corporation's revenue and margin trajectory in the Drug Manufacturers - Specialty & Generic space. | Industry headwind: clinical trial failure represents a meaningful risk for United Therapeutics Corporation and its Drug Manufacturers - Specialty & Generic peers. |
How Does UTHR Compare to Its Drug Manufacturers - Specialty & Generic Peers?
Valuation data pages: AKAN · AMPH · SXTC · ZTS · UPC · LNTH · ETON · OGI · GELS
See full Drug Manufacturers - Specialty & Generic rankings →
Which Other Stocks Score Like UTHR on Quality?
Closest companies to UTHR’s Quality of Company score of 9.6/10, across all industries.
- BKTI — BK Technologies Corporation (QOC 9.6) · analysis
- GOOG — Alphabet Inc. (QOC 9.6) · analysis
- MANH — Manhattan Associates, Inc. (QOC 9.6) · analysis
- FIX — Comfort Systems USA, Inc. (QOC 9.6) · analysis
- FFIV — F5, Inc. (QOC 9.6) · analysis
- MSFT — Microsoft Corporation (QOC 9.5) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Drug Manufacturers - Specialty & Generic Screens Does UTHR Appear In?
So Is United Therapeutics Corporation (UTHR) Worth Buying in 2026?
Our models don't have a clear verdict on United Therapeutics Corporation. At $500.35 vs. $548.31 median fair value, the median upside of +9.6% masks significant model disagreement (+154.9% spread). With quality at 9.6/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.
These are quantitative model outputs, not investment recommendations. United Therapeutics Corporation's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About UTHR Stock?
Should I buy UTHR stock right now?
Based on CirclFi's multi-model analysis, 6 of 11 models see upside for UTHR at $500.35. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 9.6/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in United Therapeutics Corporation?
Key risks include: wide model disagreement (235% spread), signaling high uncertainty; general market and sector-specific risks affecting Drug Manufacturers - Specialty & Generic companies. Always diversify and consult a financial advisor.
How does UTHR compare to its competitors?
Among Drug Manufacturers - Specialty & Generic peers, UTHR holds a Quality Score of 9.6/10. Comparable companies include AKAN (QOC 1.4), AMPH (QOC 9.4), SXTC (QOC 1.5). The relative ranking helps investors identify whether UTHR offers better fundamental quality than alternatives in the same sector.
Is UTHR a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. UTHR's Quality Score of 9.6/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy UTHR at?
CirclFi does not provide target buy prices or price alerts. However, our 11 active models produce fair value estimates ranging from $330.16 to $1105.10. At $500.35, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for UTHR.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad